A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral Therapy
Year: 2013
Type: article
Study design: Clinical Trial
Abstract: BACKGROUND: Transcriptionally silent human immunodeficiency virus type 1 (HIV-1) DNA persists in resting memory CD4(+) T cells despite antiretroviral therapy. In a primary cell model, the antialcoholism drug disulfiram has been shown to induce HIV-1 transcription in latently infected resting memory CD4(+) T cells at concentrations achieved in vivo. METHODS: We conducted a single-arm pilot study to evaluate whether 500 mg of disulfiram administered daily for 14 days to HIV-1-infected individuals on stable suppressive antiretroviral therapy would result in reversal of HIV-1 latency with a concomitant transient increase in residual viremia or depletion of the latent reservoir in resting memory CD4(+) T cells. RESULTS: Disulfiram was safe and well tolerated. There was a high level of subject-to-subject variability in plasma disulfiram levels. The latent reservoir did not change significantly (1.16-fold change; 95% confidence interval [CI], .70- to 1.92-fold; P = .56). During disulfiram administration, residual viremia did not change significantly compared to baseline (1.53-fold; 95% CI, .88- to 2.69-fold; P = .13), although residual viremia was estimated to increase by 1.88-fold compared to baseline during the postdosing period (95% CI, 1.03- to 3.43-fold; P = .04). In a post hoc analysis, a rapid and transient increase in viremia was noted in a subset of individuals (n = 6) with immediate postdose sampling (HIV-1 RNA increase, 2.96-fold; 95% CI, 1.29- to 6.81-fold; P = .01). CONCLUSIONS: Administration of disulfiram to patients on antiretroviral therapy does not reduce the size of the latent reservoir. A possible dose-related effect on residual viremia supports future studies assessing the impact of higher doses on HIV-1 production. Disulfiram affects relevant signaling pathways and can be safely administered, supporting future studies of this drug.
Source: Clinical Infectious Diseases
DOI: 10.1093/cid/cit813
Language: English
Topic: HIV Research and Treatment
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: bronze
Funders: Howard Hughes Medical Institute, amfAR, The Foundation for AIDS Research, Johns Hopkins University, National Institutes of Health, U.S. Public Health Service, Center for AIDS Research, University of Washington, University of California, San Francisco, Center for AIDS Research, Johns Hopkins University, National Institute of Mental Health, National Institute of Allergy and Infectious Diseases, National Center for Research Resources, Center for AIDS Prevention Studies, University of California, San Francisco, National Center for Advancing Translational Sciences
Awards: G1012248884, G1489286228, Clinical and Translational Science Institute, Impact of HIV-associated inflammation on disease, G202509323, DARE: Delaney AIDS Research Enterprise to find a cure., G6714156533, Institute for Clinical and Translational Research, G7998845928, Martin Delaney Collaboratory to Eradicate HIV-1 Infection, The Johns Hopkins Center for AIDS Research (JHU CFAR), Center for AIDS Prevention Studies (CAPS), UCSF-Bay Area Center for AIDS Research
OpenAlex ID: W2151980311
